Reuters logo
Australia's CSL says no change to guidance
April 23, 2010 / 4:30 AM / in 7 years

Australia's CSL says no change to guidance

MELBOURNE, April 23 (Reuters) - Australian blood products maker CSL (CSL.AX) said on Friday it had no reason to change its earnings guidance, despite its shares diving following a negative outlook from a competitor.

CSL shares slumped 7.3 percent to A$33.93 on eight times average daily volume, after U.S. rival Baxter International Inc (BAX.N) cut its full-year profit forecast on health reform costs and a weaker plasma protein market, sending its shares down 13 percent [ID:nN22225945] (Reporting by Victoria Thieberger; editing by Balazs Koranyi)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below